1 within 30 days after cardiac surgery was our
primary outcome measure.
2 Ventilator-free days was used as
primary outcome measure.
3 The 6-month recurrence rate was the
primary outcome measure.
4 27-hydroxycholesterol levels in serum as the
primary outcome measure.
5 ed by the presence or absence of SCT was the
primary outcome measure.
6 Time to diagnosis of AF was the
primary outcome measure.
7 gdala lesions reduced loss adaptation in the
primary outcome measure.
8 Change in central subfield thickness was the
primary outcome measure.
9 .0% without antiglycemic medication) was the
primary outcome measure.
10 rking memory, and processing speed) were the
primary outcome measures.
11 n and last follow-up (up to 1 year) were the
primary outcome measures.
12 tion of deuterated water) MPS responses, the
primary outcome measures.
13 atients completed the study duration for the
primary outcome measure (
43 were women [41%]).
14 not reduce symptoms of nausea, based on the
primary outcome measure (
46% reduction in the VAS score
15 The
primary outcome, measured after listening to the entire
16 ne IOP < 25 mm Hg in both studies (ROCKET-2,
primary outcome measure and population, ROCKET-1, post h
17 and in vivo assays using angiogenesis as the
primary outcome measure and the mechanisms through which
18 Self-reported
primary outcome measures and possible recall bias.
19 LogMAR visual acuity was the
primary outcome measure,
and anatomic characteristics we
20 Eye pain intensity was the
primary outcome measure,
and interference with quality o
21 linical trials now use itch measurement as a
primary outcome measure,
and steps toward the standardiz
22 have been conducted using dactylitis as the
primary outcome measure,
and the current knowledge comes
23 ower extremity Fugl-Meyer assessment [LE-FM;
primary outcome measure])
and neurophysiological (change
24 total of 779 patients provided data for the
primary outcome measure at baseline and at least 1 follo
25 mg, at baseline and every 4 weeks, with the
primary outcome measured at 6 months.
26 f participants enrolled, 139 (94%) completed
primary outcome measures at 3 months and 133 (90%) compl
27 The
primary outcome, measured at 24 months of corrected age,
28 The
primary outcome, measured at the end of the school term,
29 ow-up was for 2 years after the surgery; the
primary outcomes, measured at 1 year and 2 years, were p
30 ablation zone volumes were calculated as the
primary outcome measure by using triphenyltetrazolium ch
31 The
primary outcome, measured by the trial statistician who
32 The
primary outcome measured change in %CD38+HLA-DR+ CD8+ T
33 from start of treatment to "presumed cure" (
primary outcome measure,
defined as a closed epithelial
34 group acts as a test-retest control for the
primary outcome measure examined in this study, change i
35 However, the
primary outcome measure failed to capture differences in
36 Physical function was found to be a suitable
primary outcome measure for a future trial; adjusted mea
37 the percentage change from screening as the
primary outcome measure for statistical analysis of chan
38 The
primary outcome measure for this study was the pain scor
39 e 95% uncertainty intervals (UIs) around our
primary outcome measures for each intervention scenario.
40 Assessing
primary outcome measures for groups that received tDCS a
41 The
primary outcome measures for the study were coverage of
42 Secondary outcomes were consistent with the
primary outcome measure in reflecting better outcomes as
43 The
primary outcome measure in this study was steroid-free r
44 mbulant patients with DMD; both of which are
primary outcome measures in clinical trials.
45 The
primary outcome, measured in the fourth year, was the pr
46 Primary outcome measures included acceptability (retenti
47 Primary outcome measures included change in proteinuria
48 Our
primary outcome measures included IVCM and histopatholog
49 Primary outcome measures included lagophthalmos on blink
50 Primary outcome measures included the incidence of all R
51 The
primary outcome measures included the size of the epithe
52 The
primary outcome measure is agreement between TRI results
53 The
primary outcome measure is the rate of surgical failure,
54 mputed tomography angiography, we assessed 3
primary outcome measures:
left ventricular (LV) systolic
55 The
primary outcome measure,
MPA concentration (<0.1 ng/mL)
56 ably reproduce the statistically significant
primary outcome measure of the clinical trial.
57 The
primary outcome measure of the study was overall surviva
58 The
primary outcome measure of the trial is the modified Ran
59 The
primary outcome measure of tic severity was the Yale Glo
60 e any significant additional benefits in the
primary outcome measures of muscle mass, strength, or co
61 To determine
primary outcome measures of peak power and oxygen consum
62 For the
primary outcome, measures of risk discrimination showed
63 ed movements and vocalisations should be the
primary outcome measure,
rather than subjective scales o
64 ements associated with CBT were found on the
primary outcome measures relating to quality of life (us
65 Although the
primary outcome measure result includes the prespecified
66 e interaction effect was significant for the
primary outcome measure,
the HAM-D-6.
67 difference from placebo was detected on the
primary outcome measure,
the parent-rated Aberrant Behav
68 hildren with ASD [as measured by the trial's
primary outcome measure,
the Social Responsiveness Scale
69 PRIMARY OUTCOME MEASURE:
Uncorrected (UCDVA) and best-co
70 Primary outcome measures varied across the trials analys
71 The change from baseline to month 24 on the
primary outcome measure was 0.18 for olesoxime and -1.82
72 The
primary outcome measure was 3-y radiographic lesion prog
73 The
primary outcome measure was 30-day ERI.
74 terest were hospital characteristics and the
primary outcome measure was 30-day mortality.
75 The
primary outcome measure was 5-year overall survival.
76 The
primary outcome measure was 6-min walking distance (6MWD
77 The
primary outcome measure was 90-day mortality, and main s
78 The
primary outcome measure was a change in maximum keratome
79 The
primary outcome measure was a comparison of the DISCERN
80 The
primary outcome measure was a composite endpoint of card
81 The
primary outcome measure was a composite of all-cause dea
82 The
primary outcome measure was a composite of myocardial in
83 The
primary outcome measure was a positive reverse transcrip
84 The
primary outcome measure was a three-level outcome - surv
85 The best discrimination ability for the
primary outcome measure was achieved for [TIMP-2] x [IGF
86 The
primary outcome measure was adverse events in the period
87 The
primary outcome measure was agreement between catheteriz
88 The
primary outcome measure was all-cause mortality rate at
89 The
primary outcome measure was all-cause mortality within 3
90 The
primary outcome measure was all-cause mortality.
91 Primary outcome measure was all-cause mortality.
92 Main Outcomes and Measures: The
primary outcome measure was all-cause mortality.
93 ine deficiency has been completed in which a
primary outcome measure was an assessment of the neurobe
94 The
primary outcome measure was analysed using linear regres
95 The
primary outcome measure was anterior chamber cell grades
96 The
primary outcome measure was aseptic revision, defined as
97 Our
primary outcome measure was association between age, typ
98 The
primary outcome measure was association between binary P
99 The
primary outcome measure was average pain score 1 month a
100 Primary outcome measure was best corrected LogMAR visual
101 The
primary outcome measure was best-corrected visual acuity
102 The
primary outcome measure was BSCVA at 12 months after sur
103 The
primary outcome measure was change from baseline compare
104 The
primary outcome measure was change from baseline to day
105 The
primary outcome measure was change in antimicrobial pres
106 The
primary outcome measure was change in best corrected vis
107 The
primary outcome measure was change in BMI over 5 years.
108 The
primary outcome measure was change in choice reaction ti
109 Primary outcome measure was change in HbA1c level after
110 The
primary outcome measure was change in peak oxygen consum
111 The
primary outcome measure was change in score on the Montg
112 The
primary outcome measure was change in serum zinc concent
113 The
primary outcome measure was change in sickness absence a
114 The
primary outcome measure was change in the Hamilton Depre
115 The
primary outcome measure was change in the mean best corr
116 The
primary outcome measure was change in total RNP area (in
117 The
primary outcome measure was change in walk time on a tre
118 The
primary outcome measure was child weight loss (body mass
119 The
primary outcome measure was clinical event rates, measur
120 The
primary outcome measure was clinical relapse, defined as
121 The
primary outcome measure was collected in 98% of patients
122 The
primary outcome measure was conversion from caries-free
123 The
primary outcome measure was conversion from caries-free
124 The
primary outcome measure was correction of head tilt.
125 The
primary outcome measure was cortical thickness.
126 The
primary outcome measure was death, myocardial infarction
127 The
primary outcome measure was deep surgical site infection
128 The
primary outcome measure was depression symptom severity
129 The
primary outcome measure was detection of asymptomatic tu
130 The
primary outcome measure was determining the incidence of
131 The
primary outcome measure was development of >/=1 SAE; sec
132 The
primary outcome measure was development of inhibitors (n
133 The
primary outcome measure was device retention at 24 and 6
134 Primary outcome measure was eradication of seeds and glo
135 The
primary outcome measure was event-free survival measured
136 The
primary outcome measure was factors associated with the
137 The
primary outcome measure was fatigue severity assessed us
138 The
primary outcome measure was freedom from distant metasta
139 The
primary outcome measure was full-scale intelligence quot
140 The
primary outcome measure was global cognitive performance
141 Primary outcome measure was hazard ratio (HR) of failure
142 The
primary outcome measure was health-related quality of li
143 Our
primary outcome measure was HIV infection status, as det
144 The
primary outcome measure was HR.
145 The
primary outcome measure was hydrocortisone-induced Delta
146 The
primary outcome measure was improvement in the Internati
147 The
primary outcome measure was in-hospital major adverse ca
148 The
primary outcome measure was in-hospital mortality.
149 Our
primary outcome measure was in-hospital mortality.
150 Primary outcome measure was incidence and severity of sy
151 The
primary outcome measure was incidence of postoperative i
152 Primary outcome measure was intraocular pressure (IOP) r
153 Primary outcome measure was intraocular pressure (IOP).
154 The
primary outcome measure was late toxicity.
155 The
primary outcome measure was left ventricular ejection fr
156 The
primary outcome measure was macular thickness.
157 Primary outcome measure was mean change from baseline CS
158 The prespecified
primary outcome measure was mean change in BCVA from bas
159 Primary outcome measure was mean reduction in Montgomery
160 The
primary outcome measure was methyl aminolevulinate-induc
161 The
primary outcome measure was mortality beyond 1 year afte
162 The
primary outcome measure was mortality within 90 days of
163 The
primary outcome measure was net health benefit (NHB), wh
164 The
primary outcome measure was new or progressive multiple
165 Our
primary outcome measure was overall firearm-related mort
166 The
primary outcome measure was overall mortality (censored
167 The
primary outcome measure was overall survival (defined as
168 The
primary outcome measure was overall survival, and primar
169 The
primary outcome measure was overall survival.
170 The
primary outcome measure was overall survival; short-term
171 Primary outcome measure was patient utilization of outpa
172 The
primary outcome measure was percentage of eyes with impr
173 Our
primary outcome measure was potential deceased organ don
174 The median follow-up was 6.9 y, and the
primary outcome measure was prostate-cancer-specific mor
175 The
primary outcome measure was quality-adjusted life-years
176 The
primary outcome measure was reduction in homeostasis mod
177 The
primary outcome measure was remission, assessed with the
178 The
primary outcome measure was resolution of definite non-a
179 The
primary outcome measure was restoration of a completely
180 Our
primary outcome measure was self-reported total opioid u
181 The
primary outcome measure was speech comprehension score o
182 The
primary outcome measure was SSI score 24 hours after inf
183 The
primary outcome measure was stabilization of keratoconus
184 The
primary outcome measure was success rates after ALPI at
185 The
primary outcome measure was surgical success (intraocula
186 Primary outcome measure was surgical success defined in
187 The
primary outcome measure was surgical wound complications
188 The
primary outcome measure was survival at hospital dischar
189 The
primary outcome measure was survival to hospital dischar
190 The
primary outcome measure was test positivity rate of SARS
191 The
primary outcome measure was the Alzheimer's Disease Coop
192 Measurements: The
primary outcome measure was the Alzheimer's Disease Coop
193 The
primary outcome measure was the area under the curve (AU
194 The
primary outcome measure was the Cambridge Face Memory Te
195 The
primary outcome measure was the change in 6-minute walk
196 Primary outcome measure was the change in central macula
197 The
primary outcome measure was the change in DAS28-ESR betw
198 The
primary outcome measure was the change in the 17-item Ha
199 The
primary outcome measure was the change in the average NF
200 The
primary outcome measure was the change in the Epworth Sl
201 The
primary outcome measure was the change in the preoperati
202 Primary outcome measure was the change in visual acuity
203 The
primary outcome measure was the Clinician-Administered P
204 The
primary outcome measure was the dermatological sum score
205 The
primary outcome measure was the determination of the cha
206 The
primary outcome measure was the difference between clini
207 The
primary outcome measure was the difference between group
208 Primary outcome measure was the difference in change in
209 Our
primary outcome measure was the direction and magnitude
210 Based on a previous report, the
primary outcome measure was the effect of intra-epoch ti
211 The
primary outcome measure was the frequency of adverse eve
212 The
primary outcome measure was the frequency of AEs.
213 The
primary outcome measure was the HCV status (antibody and
214 The
primary outcome measure was the incidence of hospital re
215 The
primary outcome measure was the incidence of in-hospital
216 The
primary outcome measure was the incremental cost-effecti
217 The
primary outcome measure was the incremental cost-effecti
218 The
primary outcome measure was the investigator-rated ADHD
219 The
primary outcome measure was the MFIS measured while taki
220 The
primary outcome measure was the Montogmery Asberg Depres
221 The
primary outcome measure was the negative predictive valu
222 The
primary outcome measure was the occurrence of NIU with t
223 The
primary outcome measure was the odds ratio (OR) for the
224 The
primary outcome measure was the PANSS negative factor sc
225 The
primary outcome measure was the percentage of accuracy o
226 The
primary outcome measure was the percentage of families s
227 The
primary outcome measure was the physical component summa
228 The
primary outcome measure was the Positive and Negative Sy
229 aract surgery with IOL implantation, and the
primary outcome measure was the presence or absence of s
230 The
primary outcome measure was the proportion of patients w
231 Primary outcome measure was the proportion of patients w
232 The
primary outcome measure was the proportion of rA TTEs.
233 The
primary outcome measure was the proportions of participa
234 The
primary outcome measure was the rate of antibiotic items
235 The
primary outcome measure was the rate of recurrent biliar
236 The
primary outcome measure was the rate of surgical failure
237 The
primary outcome measure was the RBANS total scale score,
238 Main Outcomes and Measures: The
primary outcome measure was the sensitivity and specific
239 The
primary outcome measure was the shift in the degree of d
240 The
primary outcome measure was the shift in the degree of d
241 The
primary outcome measure was to characterize the clinical
242 The
primary outcome measure was volumetric MRI percentage br
243 The
primary outcome measured was the postoperative early and
244 The
primary outcome measured was total antibiotic days of th
245 The
primary outcome measured was total antibiotic-days of th
246 The
primary-outcome measure was analyzed with an ordinal met
247 Recurrence-free survival (RFS), the
primary outcome measure,
was evaluated according to Metr
248 Primary outcome measures were 28-day mortality, recurren
249 Primary outcome measures were annualized changes in caro
250 Primary outcome measures were assessed at 6 months and m
251 The co-
primary outcome measures were assessor rated symptom sev
252 The co-
primary outcome measures were BMI and 20-item Depression
253 Intention-to-treat
primary outcome measures were changes in HDRS17 and GAF
254 Primary outcome measures were changes in perimetric mean
255 The
primary outcome measures were clinicopathological charac
256 Main Outcomes and Measures: The
primary outcome measures were clinicopathological charac
257 The
primary outcome measures were confounding factors affect
258 The
primary outcome measures were depression (measured by th
259 The
primary outcome measures were diagnostic accuracy, sensi
260 Primary outcome measures were errors during the real pro
261 Two composite
primary outcome measures were evaluated: (i) CVD events/
262 Primary outcome measures were fever clearance time and f
263 Primary outcome measures were final mean changes in BCVA
264 The
primary outcome measures were for insomnia, paranoia, an
265 Primary outcome measures were graft and patient survival
266 Primary outcome measures were IBS Symptom Severity Score
267 The
primary outcome measures were IOP reduction and the succ
268 The
primary outcome measures were levels of plasma metabolit
269 Primary outcome measures were mean change in (1) tear os
270 Primary outcome measures were mean refracted BCVA and pr
271 The
primary outcome measures were overall mortality and canc
272 The
primary outcome measures were positive donor rim fungal
273 Primary outcome measures were positive margin and re-exc
274 rventions; and additional access procedures (
primary outcome measures were previously reported).
275 The
primary outcome measures were rate of change in body wei
276 Primary outcome measures were reoperation due to hernia
277 Primary outcome measures were the apnea-hypopnea index (
278 The
primary outcome measures were the classification accurac
279 The
primary outcome measures were the Evaluation du Vecu de
280 Primary outcome measures were the frequency of clinical
281 The
primary outcome measures were the frequency of complete
282 Primary outcome measures were the mean and median CMS pa
283 The
primary outcome measures were the mean change in best co
284 The
primary outcome measures were the number of colony-formi
285 The
primary outcome measures were the occurrence of eyelid o
286 The
primary outcome measures were the postintervention chang
287 Primary outcome measures were the prevalence of diagnose
288 Primary outcome measures were the prevalence of frailty
289 Primary outcome measures were the Rating for Premenstrua
290 The
primary outcome measures were the suicide items from cli
291 Primary outcome measures were treatment-emergent AE (TEA
292 Main Outcomes and Measures: The
primary outcome measures were tumor characteristics, pro
293 Primary outcome measures were white matter hyperintensit
294 The dual
primary outcome measures were worst and average pain sco
295 Primary outcome measures were: time taken, path length,
296 The
primary outcomes measured were visual acuity, contrast a
297 HRs for OS (the
primary outcome measure)
were pooled to provide an aggre
298 Main Outcomes and Measures: HRs for OS (the
primary outcome measure)
were pooled to provide an aggre
299 n the ocular surface severity scores was the
primary outcome measure,
while change in CDVA was the se
300 0 [complete disability]) at 6 months was the
primary outcome measure,
with a minimal clinically impor